抗生素序贯疗法对社区获得性肺炎治疗的临床观察

目的探讨抗生素序贯治疗法对社区获得性肺炎的临床疗效。方法对医院62例患者随机分配为治疗组和对照组。结果两组治疗效果并无显著的差异(P>0.05);治疗组与对照组的时间相比,差异有统计学意义(P<0.01);治疗组与对照组的费用比较,显著减少(P<0.01)。结论抗生素的序贯疗法是一种安全、有效、经济、方便的治疗方法。

中医序贯疗法治疗月经不调100例临床效果研究

目的本文主要研究中医序贯疗法在治疗月经不调100例临床效果显示。方法选取2016年4月至2017年1月与我院进行就诊100例月经不调患者为本次的研究对象,将其随机分为观察组和对照组两组,每组月经不调患者50例,其中将观察组月经不调患者采取中医序贯治疗法进行治疗,对照组患者采取普通的雌孕激素进行治疗,经过一段时间的治疗之后,对比两组月经不调患者的治疗效果。结果观察组月经不调患者治疗总有效率96.0%,对照组月经不调患者治疗总有效率78.0%,观察组月经不调患者治疗总有效率相对对照组差异显著。结论针对月经不调患者采取中医序贯治疗法,能够有效帮助患者调理月经,具有非常好的临床效果,值得临床广泛推广。

阿莫西林克拉维酸钾联合阿奇霉素序贯疗法治疗社区获得性肺炎临床研究

目的:研究阿莫西林克拉维酸钾联合阿奇霉素序贯疗法治疗社区获得性肺炎的效果。方法:2019年2月-2019年7月收治社区获得性肺炎患者96例,随机分为两组各48例。对照组给予阿莫西林克拉维酸钾联合阿奇霉素常规静脉给药治疗,观察组给予阿莫西林克拉维酸钾联合阿奇霉素序贯疗法治疗,两组疗程均为7~14 d。比较两组细菌学清除率、不良反应发生率及住院时间。结果:对照组治疗后不良反应发生率高于观察组,差异有统计学意义(P<0.05)。观察组平均住院时间显著低于对照组,差异有统计学意义(P<0.05)。两组细菌清除率比较,差异无统计学意义(P>0.05)。结论:阿莫西林克拉维酸钾联合阿奇霉素序贯疗法治疗社区获得性肺炎能够收到良好效果,且不良反应发生率低。

加替沙星序贯给药治疗下呼吸道细菌性感染

目的 :评价加替 (Gatifloxacin)沙星先静脉、后口服序贯给药治疗社区获得性肺炎 (CAP)为主的下呼吸道感染的疗效与安全性。 方法 :采用随机对照盲法平行试验设计 ,入选并完成病例 5 2例 ,其中CAP 5 1例 ,慢性支气管炎急性发作 (AECB) 1例。试验组 (2 6例 )给予加替沙星注射液 4 0 0mg ,每天 1次静脉滴注 ,共 3～ 5天 ,继以加替沙星片 4 0 0mg ,每天 1次口服 ;对照组 (2 6例 )给予左旋氧氟沙星注射液 4 0 0mg/d ,分 2次静脉滴注 ,共 3～ 5天 ,继续以每天左旋氧氟沙星片 4 0 0mg/d ,分 2次服用 ,总疗程均为 7～ 1 4天。 结果 :试验组和对照组临床可评价的病例均为 2 6例 ,有效率分别为 1 0 0 % (2 6 /2 6 )和 96 .2 % (2 5 /2 6 )。痊愈率分别为 76 .9% (2 0 /2 6 )和 6 5 .4 % (1 7/2 6 ) ,差异均不显著 (P >0 .0 5 )。试验组和对照组可作细菌学评价病例分别为 1 8例和 1 9例 ,细菌清除率分别为 94 .4 %(1 7/1 8)和 6 8.4 % (1 3/1 9) (P >0 .0 5 )。试验组和对照组不良反应发生率分别为 30 .8% (8/2 6 )和 1 1 .5 % (3/6 ) ,(P>0 .0 5 )。实验室检查异常发生率各为 4 2 .3% (1 2 /2 6 )和 2 6 .9% (7/2 6 ) (P >0 .0 5 ) ,均系轻度 ,并呈一过性 ,无需处理。 结论 :本研究结果显示 。

首次根除幽门螺杆菌失败后不同补救方法的疗效分析

目的探讨首次根除幽门螺杆菌失败后不同补救方法的疗效。方法选取首次根除幽门螺杆菌失败后的患者312例,随机分为观察组和对照组各156例,观察组应用改良序贯治疗法,对照组应用四联疗法进行治疗,比较两组患者幽门螺杆菌根除率,不良反应发生率及患者满意度,并在治疗结束后对两组复发率进行比较。结果观察组患者幽门螺杆菌根除率(92.31%)优于对照组(73.72%),差异有统计学意义(P<0.05);观察组的总满意度(94.87%)优于对照组(86.54%),差异有统计学意义(P<0.05);两组不良反应均较轻微,不影响治疗,观察组不良反应发生率为5.77%,对照组为7.69%,差异无统计学意义(P>0.05);观察组1年复发率(4.49%)低于对照组(12.82%),差异有统计学意义(P<0.05)。结论对于首次根除幽门螺杆菌失败后的补救方法,应用改良序贯治疗法疗效优于传统四联疗法,且安全有效,不良反应较少,值得临床进一步推广研究。

支气管肺炎后慢性咳嗽130例临床分析

目的:分析130例支气管肺炎后慢性咳嗽的原因、特点,提出治疗措施。方法:回顾性分析收治的支气管肺炎1 063例中有慢性咳嗽130例,分析其咳嗽特点、探讨发病机制。结果:130例中42例经抗生素治愈,抗生素治疗无效88例,其中抗过敏治愈32例,应用支气管扩张剂治愈54例,自愈2例。结论:在基层,支气管肺炎后慢性咳嗽可采取序贯治疗。

Helicobacter pylori eradication: Sequential therapy and Lactobacillus reuteri supplementation

AIM:To evaluate the role of sequential therapy and Lactobacillus reuteri (L. reuteri ) supplementation, in the eradication treatment of Helicobacter pylori (H. pylori ). METHODS:H. pylori infection was diagnosed in 90 adult dyspeptic patients. Patients were excluded if previously treated for H. pylori infection or if they were taking a proton pump inhibitor (PPI), H2-receptor antagonist or antibiotics. Patients were assigned to receive one of the following therapies:(1) 7-d triple therapy (PPI plus clarithromycin and amoxicillin or metronidazole) plus L. reuteri supplementation dur- ing antibiotic treatment; (2) 7-d triple therapy plus L. reuteri supplementation after antibiotic treatment; (3) sequential regimen (5-d PPI plus amoxicillin therapy followed by a 5-d PPI, clarithromycin and tinidazole) plus L. reuteri supplementation during antibiotic treatment; and (4) sequential regimen plus L. reuteri supplementation after antibiotic treatment. Successful eradication therapy was defined as a negative urea breath test at least 4 wk following treatment. RESULTS:Ninety adult dyspeptic patients were en- rolled, and 83 (30 male, 53 female; mean age 57 ± 13 years) completed the study. Nineteen patients were administered a 7-d triple treatment:11 with L. reuteri supplementation during and 8 after therapy. Sixty-four patients were administered a sequential regimen:32 with L. reuteri supplementation during and 32 after therapy. The eradication rate was significantly higher in the sequential group compared with the 7-d triple regimen (88% vs 63%, P = 0.01). No difference was found between two types of PPI. No difference in erad- ication rates was observed between patients submitted to L. reuteri supplementation during or after antibiotic treatment. Compliance with therapy was excellent in all patients. No difference in adverse effects was observed between the different antibiotic treatments and between patients submitted to L. reuteri supplementation during and after antibiotic treatment. There was a low incidence of adverse effects in all groups of patients with sequential therapy, probably due to the presence of the L. reuteri supplementation. CONCLUSION:The sequential treatment regimen achieved a significantly higher eradication rate of H. pylori compared with standard 7-d regimen. L. reuteri supplementation could reduce the frequency and the intensity of antibiotic-associated side-effects.